137 related articles for article (PubMed ID: 2396995)
1. Kinetics of inhibition of platelet calpain II by human kininogens.
Bradford HN; Schmaier AH; Colman RW
Biochem J; 1990 Aug; 270(1):83-90. PubMed ID: 2396995
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation.
Meloni FJ; Schmaier AH
J Biol Chem; 1991 Apr; 266(11):6786-94. PubMed ID: 2016293
[TBL] [Abstract][Full Text] [Related]
3. High molecular weight kininogen is an inhibitor of platelet calpain.
Schmaier AH; Bradford H; Silver LD; Farber A; Scott CF; Schutsky D; Colman RW
J Clin Invest; 1986 May; 77(5):1565-73. PubMed ID: 2422211
[TBL] [Abstract][Full Text] [Related]
4. Contiguous binding and inhibitory sites on kininogens required for the inhibition of platelet calpain.
Bradford HN; Jameson BA; Adam AA; Wassell RP; Colman RW
J Biol Chem; 1993 Dec; 268(35):26546-51. PubMed ID: 8253784
[TBL] [Abstract][Full Text] [Related]
5. High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage.
Meloni FJ; Gustafson EJ; Schmaier AH
Blood; 1992 Mar; 79(5):1233-44. PubMed ID: 1536948
[TBL] [Abstract][Full Text] [Related]
6. High-molecular-mass and low-molecular-mass kininogens block plasmin-induced platelet aggregation by forming a complex with kringle 5 of plasminogen/plasmin.
Selim TE; Ghoneim HR; Uknis AB; Colman RW; DeLa Cadena RA
Eur J Biochem; 1997 Dec; 250(2):532-8. PubMed ID: 9428707
[TBL] [Abstract][Full Text] [Related]
7. Modulation of thrombin-induced platelet aggregation by inhibition of calpain by a synthetic peptide derived from the thiol-protease inhibitory sequence of kininogens and S-(3-nitro-2-pyridinesulfenyl)-cysteine.
Puri RN; Matsueda R; Umeyama H; Bradford HN; Colman RW
Eur J Biochem; 1993 May; 214(1):233-41. PubMed ID: 8389701
[TBL] [Abstract][Full Text] [Related]
8. Determination of the bifunctional properties of high molecular weight kininogen by studies with monoclonal antibodies directed to each of its chains.
Schmaier AH; Schutsky D; Farber A; Silver LD; Bradford HN; Colman RW
J Biol Chem; 1987 Jan; 262(3):1405-11. PubMed ID: 2433279
[TBL] [Abstract][Full Text] [Related]
9. Insights on monoclonal antibodies to kininogens' heavy chain which influence kininogens' binding to platelets.
Jiang Y; Nawarawong W; Meloni FJ; Schmaier AH
Thromb Haemost; 1992 Aug; 68(2):143-8. PubMed ID: 1412158
[TBL] [Abstract][Full Text] [Related]
10. Expression of thrombospondin 1 on the surface of activated platelets mediates their interaction with the heavy chains of human kininogens through Lys 244-Pro 254.
DeLa Cadena RA; Kunapuli SP; Walz DA; Colman RW
Thromb Haemost; 1998 Jan; 79(1):186-94. PubMed ID: 9459346
[TBL] [Abstract][Full Text] [Related]
11. Bradykinin regulates the expression of kininogen binding sites on endothelial cells.
Zini JM; Schmaier AH; Cines DB
Blood; 1993 Jun; 81(11):2936-46. PubMed ID: 8388750
[TBL] [Abstract][Full Text] [Related]
12. Progress curve analysis of the kinetics with which blood coagulation factor XIa is inhibited by protease nexin-2.
Scandura JM; Zhang Y; Van Nostrand WE; Walsh PN
Biochemistry; 1997 Jan; 36(2):412-20. PubMed ID: 9003194
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of chicken calpain II by proteins of the cystatin superfamily and alpha 2-macroglobulin.
Crawford C
Biochem J; 1987 Dec; 248(2):589-94. PubMed ID: 2449169
[TBL] [Abstract][Full Text] [Related]
14. The carboxyl terminus of bradykinin and amino terminus of the light chain of kininogens comprise an endothelial cell binding domain.
Hasan AA; Cines DB; Zhang J; Schmaier AH
J Biol Chem; 1994 Dec; 269(50):31822-30. PubMed ID: 7989355
[TBL] [Abstract][Full Text] [Related]
15. Interaction of human calpains I and II with high molecular weight and low molecular weight kininogens and their heavy chain: mechanism of interaction and the role of divalent cations.
Ishiguro H; Higashiyama S; Namikawa C; Kunimatsu M; Takano E; Tanaka K; Ohkubo I; Murachi T; Sasaki M
Biochemistry; 1987 May; 26(10):2863-70. PubMed ID: 3038169
[TBL] [Abstract][Full Text] [Related]
16. Proteolytic degradation of high molecular weight kininogen in acute thrombotic thrombocytopenic purpura.
Pavord S; Kelton JG; Warner MN; Moore JC; Warkentin TE; Hayward CP
Br J Haematol; 1997 Jun; 97(4):762-7. PubMed ID: 9217174
[TBL] [Abstract][Full Text] [Related]
17. Opposing effects of low and high molecular weight kininogens on cell adhesion.
Asakura S; Yang W; Sottile J; Zhang Q; Jin Y; Ohkubo I; Sasaki M; Matsuda M; Hirata H; Mosher DF
J Biochem; 1998 Sep; 124(3):473-84. PubMed ID: 9722655
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cell binding and thrombin inhibitory regions on kininogens' heavy chain.
Jiang YP; Schmaier AH
Agents Actions Suppl; 1992; 38 ( Pt 1)():233-40. PubMed ID: 1466275
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of a kininogen-based selective inhibitor of thrombin-induced platelet aggregation.
Matsueda R; Umeyama H; Puri RN; Bradford HN; Colman RW
Pept Res; 1994; 7(1):32-5. PubMed ID: 8019060
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of the kininogens.
Schmaier AH; Wahl R; Fisher SJ; Brenner D
Thromb Res; 1998 Dec; 92(6):293-7. PubMed ID: 9870897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
